Genetic factors and treatment of mood disorders

Bipolar Disorders

Volumn 3, Issue 6, 2001, Pages 318-324

  Alda, Martin ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Affective disorders; Antidepressants; Bipolar disorder; Genetics; Lithium; Major depression; Pharmacogenetics

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FENFLURAMINE; FLUVOXAMINE; IMIPRAMINE; LITHIUM; NORTRIPTYLINE; PAROXETINE; PINDOLOL; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR;

AFFECTIVE NEUROSIS; CONTROLLED STUDY; DRUG RESPONSE; GENETIC ASSOCIATION; HEREDITY; HUMAN; LONG TERM CARE; MEDICAL LITERATURE; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; HUMANS; MOLECULAR BIOLOGY; MOOD DISORDERS;

EID: 0035685537     PISSN: 13985647     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-5618.2001.30606.x     Document Type: Review

References (65)

1. Pharmacogenetics of antidepressants: Clinical aspects
2. A clinical analysis of the effects of tofranil in depression: Longitudinal and follow-up studies. Treatment of blood-relations
3. Differentiation of two genetically specific types of depression by the response to antidepressants
4. Differentiation of two genetically specific types of depression by the response to antidepressant drugs
5. Pharmacogenetic response to antidepressants in a multicase family with affective disorder
6. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees
7. Mode of inheritance in mood disorder families according to fluvoxamine response
8. Allelic variation of human serotonin transporter gene expression
9. A novel functional polymorphism within the promoter of the serotonin transporter gene: Possible role in susceptibility to affective disorders
10. Serotonin transporter (5-HTT) gene and bipolar affective disorder
11. Analysis and meta-analysis of two serotonin transporter gene polymorphisms in bipolar and unipolar affective disorders
12. Serotonin transporter gene and risk for bipolar affective disorder: An association study in Spanish population
13. Multimarker haplotypes within the serotonin transporter gene suggest evidence of an association with bipolar disorder
14. Lack of linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and bipolar disorder
15. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine
16. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene
17. Serotonin transporter gene polymorphism and antidepressant response
18. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression
19. Genetic variability in the promoter region of the serotonin transporter gene is associated with clinical remission of major depression after long term treatment with citalopram
20. Serotonin transporter (5-HTT) promoter genotype may influence the prolactin response to clomipramine
21. Serotonin transporter promoter polymorphism is associated with attenuated prolactin response to fenfluramine
22. Influence of a functional polymorphism within the promoter of the serotonin transporter gene on the effects of total sleep deprivation in bipolar depression
23. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder
24. Moclobemide response in depressed patients: Association study with a functional polymorphism in the monoamine oxidase - A promoter
25. Relationship between the effectiveness of lithium therapy and family history
26. Factors associated with treatment success in lithium carbonate prophylaxis: Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group
27. Family history of manic-depressive and endogenous depressive patients and clinical effect of treatment with lithium
28. Therapy and prophylaxis of manic-depressive psychosis with lithium carbonate, with respect to possibility of prediction of the therapeutic result
29. Prediction of affective psychoses response to lithium prophylaxis: He role of socio-demographic, clinical, psychological and biological variables
30. Outcomes on lithium treatment as a tool for genetic studies in affective disorders
31. Who responds to prophylactic lithium?
32. Lithium response and genetics of affective disorders
33. Lithium carbonate prophylaxis failure
34. "Lithium non-responders" in a lithium clinic
35. A family study of bipolar I disorder in adolescence: Early onset of symptoms linked to increased familial loading and lithium resistance
36. Relationship between prophylactic effect of lithium therapy and family history of affective disorders
37. Family history and symptom levels during treatment for bipolar I affective disorder
38. A plea for integrity of the bipolar disorder concept
39. Clinical course of affective disorders: Were Emil Kraepelin and Jules Angst Wrong?
40. The implications of genetic studies of major mood disorders for clinical practice
41. Manic-depressive illness in children and effect of treatment with lithium carbonate
42. Lithium carbonate treatment of select behavior disorders in children suggesting manic-depressive illness
43. Lithium carbonate use in children and adolescents. A survey of the literature
44. Lithium in children of lithium-responding parents
45. Psychiatric symptoms and syndromes among adolescent children of parents with lithium-responsive or lithium-nonresponsive bipolar disorder
46. The challenge of predicting response to stabilising lithium treatment. The importance of patient selection
47. Is response to prophylactic lithium a familial trait?
48. Evidence for a role of phospholipase C-gamma1 in the pathogenesis of bipolar disorder
49. The phospholipase C-g1 gene (PLCG1) and lithium-responsive bipolar disorder: Re-examination of an intronic dinucleotide repeat polymorphism
50. Lithium-responsive affective disorders: No association with the tyrosine hydroxylase gene
51. No association between chromosome-18 markers and lithium responsive affective disorders
52. MAOA: Association and linkage studies with lithium responsive bipolar disorder
53. Association and linkage analyses of CRH and PENK genes in bipolar disorder responsive to lithium: A collaborative IGSLi study
54. Association and linkage studies of candidate genes involved in GABAergic neurotransmission in lithium responsive bipolar disorder
55. Mapping susceptibility genes for bipolar disorder: A pharmacogenetic approach based on excellent response to lithium
56. Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders
57. Dopamine receptor D2 and D4 genes, GABA(A) alpha-1 subunit genes and response to lithium prophylaxis in mood disorders
58. Dopamine receptor D3 gene and response to lithium prophylaxis in mood disorders
59. Serotonin transporter gene associated with lithium prophylaxis in mood disorders
60. Lithium response: Association study with two candidate genes
61. Lack of genetic variation in the coding region of the myo-inositol monophosphatase gene in lithium-treated patients with manic depressive illness
62. Genomic structure and chromosomal localization of a human myo-inositol monophosphatase gene (IMPA)
63. The role of gene mutations of the inositol phospholipid signalling system in lithium-treated bipolar disorder
64. Chromosome 18 DNA markers and manic-depressive illness: Evidence for a susceptibility gene
65. The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness